EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Celiac disease: mechanisms and emerging therapeutics

Harrison A Besser, Chaitan Khosla

Trends in Pharmacological Sciences · 2023

DOI: 10.1016/j.tips.2023.09.006 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Trends in Pharmacological Sciences, 2023. Verfasst von Harrison A Besser und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Stanford University, Stanford, CA 94305, USA; Stanford Medical Scientist Training Program, Stanford University School of Med…. Hauptthemen laut MEDLINE: Celiac Disease. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 119 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, NIDDK NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Celiac disease (CeD) is a widespread, gluten-induced, autoimmune disorder that lacks any medicinal therapy. Towards the goal of developing non-dietary treatments for CeD, research has focused on elucidating its molecular and cellular etiology. A model of pathogenesis has emerged centered on interactions between three molecular families: specific class II MHC proteins on antigen-presenting cells (APCs), deamidated gluten-derived peptides, and T cell receptors (TCRs) on inflammatory CD4+ T cells. Growing evidence suggests that this pathogenic axis can be pharmacologically targeted to protect patients from some of the adverse effects of dietary gluten. Further studies have revealed the existence of additional host and environmental contributors to disease initiation and tissue damage. This review summarizes our current understanding of CeD pathogenesis and how it is being harnessed for therapeutic design and development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Celiac DiseaseHumansGlutensT-LymphocytesReceptors, Antigen, T-CellAntigen-Presenting Cells

Stichwörter der Autor:innen

T cellsantigen-presenting cellsautoimmunityceliac diseaseclinical trialsglutenmajor histocompatibility complextherapeuticstransglutaminase

Substanzen

GlutensReceptors, Antigen, T-Cell

Autor:innen und Institutionen

  • Department of Chemistry, Stanford University, Stanford, CA 94305, USA; Stanford Medical Scientist Training Program, Stanford University School of Medicine, Stanford, CA 94305, USA.
  • Department of Chemistry, Stanford University, Stanford, CA 94305, USA; Department of Chemical Engineering, Stanford University, Stanford, CA 94305, USA; Sarafan ChEM-H (Chemistry, Engineering and Medicine for Human Heal…

Förderung

  • NIGMS NIH HHS
  • NIDDK NIH HHS
  • National Institutes of Health
  • Stanford University

Zitieren

APA

Besser, H. A., & Khosla, C. (2023). Celiac disease: mechanisms and emerging therapeutics. Trends in Pharmacological Sciences. https://doi.org/10.1016/j.tips.2023.09.006

Vancouver

Besser HA, Khosla C. Celiac disease: mechanisms and emerging therapeutics. Trends in Pharmacological Sciences. 2023. doi:10.1016/j.tips.2023.09.006

BibTeX
@article{Besser2023,
  author = {Besser, Harrison A and Khosla, Chaitan},
  title = {Celiac disease: mechanisms and emerging therapeutics},
  journal = {Trends in Pharmacological Sciences},
  year = {2023},
  doi = {10.1016/j.tips.2023.09.006}
}
Kostenlos starten →